Pharmaceutical News

RSS

Opexa Therapeutics reports lower net loss of $1.4M for first-quarter 2010

Opexa Therapeutics, Inc., a company developing Tovaxin®, a novel T-cell therapy for multiple sclerosis (MS), today reported financial results for the quarter ended March 31, 2010 and provided an update on its corporate developments.

14 May 2010

Novel vaccines for deadly diseases to be presented at AAPS' NBC

Novel vaccines for diseases ranging from the flu to HIV highlight a week's worth of biotechnology research at the American Association of Pharmaceutical Scientists' National Biotechnology Conference. Scientists from academia, industry, and government will gather at the Hilton San Francisco Union Square Sunday, May 16 -Thursday, May 20 to share research and advances in biotherapeutics.

14 May 2010

International study to test effectiveness of celecoxib in preventing growth of precancerous polyps

Rush University Medical Center is testing whether celecoxib, known by its brand name Celebrex, can help prevent the growth of precancerous polyps that form in the colon, rectum and small intestine of children with an inheritable genetic disease called familial adenomatous polyposis.

14 May 2010

Rotavirus vaccination associated with decline in U.S. hospitalization rates for acute gastroenteritis: Study

Vaccinating infants against rotavirus, a leading cause of severe diarrhea and dehydration among babies and young children, was associated with a dramatic decline in U.S. hospitalization rates for acute gastroenteritis.

14 May 2010

Report of 2009 H1N1 influenza VLP vaccine published online

Novavax, Inc. announces the first report of a vaccine protecting ferrets against the 2009 pandemic H1N1 virus has been published in the journal Vaccine May 12, 2010 online issue.

14 May 2010

Immunosuppressive drug sirolimus improves kidney health of patients with ADPKD: Study

The immunosuppressive drug sirolimus considerably improves the kidney health of patients with autosomal dominant polycystic kidney disease, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology.

14 May 2010

ARYx Therapeutics decreases first-quarter net loss to $6.4 million

ARYx Therapeutics, Inc. today reported results of operations and provided an update on its business activities for the first quarter ended March 31, 2010.

13 May 2010

Repligen files IND for Phase 1 study of RG2833 selective HDAC-3 inhibitor for Friedreich's ataxia

Repligen Corporation announced today that it has filed an Investigational New Drug Application (IND) with the Food and Drug Administration (FDA) for a Phase 1 study of RG2833, a selective histone deacetylase 3 (HDAC-3) inhibitor. This is a double-blind, single ascending dose, Phase 1 study in healthy volunteers to evaluate the pharmacokinetic and safety profile of RG2833 in up to 40 subjects.

13 May 2010

Gene-Eden may be effective in reducing Hepatitis C viral load in people infected with virus: Review

A new review on the Amazon website suggests that the natural antiviral supplement Gene-Eden may be effective in reducing the Hepatitis C viral load in people infected with the virus.

13 May 2010

Data on Qnexa to be presented at World Congress on CODHy in Prague

VIVUS, Inc. today announced that data on Qnexa, an investigational drug candidate, will be presented at the 3rd World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension in Prague, Czech Republic.

13 May 2010

Researchers provide better understanding of anti-cell death proteins and potential antagonist to defeat them

Cancer uses devious means to evade treatment and survive. One prime example is the way tumors express anti-cell death (anti-apoptotic) proteins to resist chemotherapy and radiation. However, the Pellecchia laboratory at Sanford-Burnham Medical Research Institute has made two recent discoveries that may help curb these anti-apoptotic proteins and make current treatments more effective.

13 May 2010

Genetic Immunity formulates first topically administered nanomedicine therapeutic vaccine for HIV/AIDS

Genetic Immunity, a multi-national biopharmaceutical company developing nanomedicine vaccines today announces publication of the Company's innovative work to develop a stable liquid formulation to deliver a novel nanomedicine. Appearing in the International Journal of Pharmaceutics, the paper addresses how Genetic Immunity was able to overcome significant hurdles facing the field to successfully formulate the first topically administered nanomedicine therapeutic vaccine for the treatment of HIV/AIDS, DermaVir.

13 May 2010

Graymark Healthcare first-quarter consolidated net revenues increase 7% to $27.6 million

Graymark Healthcare, Inc. today announced progress on Fiscal 2010 Initiatives and financial results for the Quarter ending March 31, 2010.

13 May 2010

Aeterna Zentaris posts net loss of $5.9 million for first-quarter 2010

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrinology, today reported financial and operating results as at and for the three months ended March 31, 2010.

13 May 2010

Research article focuses on how IECs respond to probiotic strain B. lactis HN019

Probiotics are a group of live microorganisms administered in adequate amounts which confer a beneficial health effect on the host. This bacterial community plays a pivotal role in human nutrition and health by promoting the supply of nutrients, preventing pathogen colonization and shaping and maintaining normal mucosal immunity.

13 May 2010

ACHN reports net loss of $5.6M for first-quarter 2010: MicroStockProfit.com

MicroStockProfit.com announces an investment report featuring Achillion Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

13 May 2010

Celera to present on AIDS pandemic, AZT drugs at Computational Molecular Biology Symposium

In 1985 there was little hope for people with AIDS. Newspapers and television screens were filled with ghastly pictures of emaciated figures dying from a disease that had no cure.

13 May 2010

FDA Advisory Committee planned to review Lux Biosciences' NDA for voclosporin

Isotechnika Pharma Inc. today announced that the Dermatology and Ophthalmology Drugs Advisory Committee of the U.S. Food and Drug Administration is scheduled to review partner, Lux Biosciences', New Drug Application for voclosporin on June 28, 2010.

13 May 2010

Additional benefits of LAIAs over long-acting human insulin not been proven

It has so far not been proven that the long-acting insulin analogues (LAIAs) insulin detemir (trade name: Levemir) and insulin glargine (trade name: Lantus), which are approved for the treatment of type 1 diabetes, offer patients an additional benefit versus long-acting human insulin. This applies to adults as well as to children and adolescents. This is the result of the final report published by the Institute for Quality and Efficiency in Health Care (IQWiG) on 19 April 2010.

13 May 2010

AlphaRx continues to develop Indaflex for the Chinese market

AlphaRx, Inc., has been advised by Cypress Biosciences, its development partner for Indaflex, that Cypress is not funding development of Indaflex. Notwithstanding to the termination of all Indaflex activity in the U.S.A., AlphaRx continues to develop Indaflex for the Chinese market.

13 May 2010

Pharmaceutical News

Opexa Therapeutics reports lower net loss of $1.4M for first-quarter 2010

Novel vaccines for deadly diseases to be presented at AAPS' NBC

International study to test effectiveness of celecoxib in preventing growth of precancerous polyps

Rotavirus vaccination associated with decline in U.S. hospitalization rates for acute gastroenteritis: Study

Report of 2009 H1N1 influenza VLP vaccine published online

Immunosuppressive drug sirolimus improves kidney health of patients with ADPKD: Study

ARYx Therapeutics decreases first-quarter net loss to $6.4 million

Repligen files IND for Phase 1 study of RG2833 selective HDAC-3 inhibitor for Friedreich's ataxia

Gene-Eden may be effective in reducing Hepatitis C viral load in people infected with virus: Review

Data on Qnexa to be presented at World Congress on CODHy in Prague

Researchers provide better understanding of anti-cell death proteins and potential antagonist to defeat them

Genetic Immunity formulates first topically administered nanomedicine therapeutic vaccine for HIV/AIDS

Graymark Healthcare first-quarter consolidated net revenues increase 7% to $27.6 million

Aeterna Zentaris posts net loss of $5.9 million for first-quarter 2010

Research article focuses on how IECs respond to probiotic strain B. lactis HN019

ACHN reports net loss of $5.6M for first-quarter 2010: MicroStockProfit.com

Celera to present on AIDS pandemic, AZT drugs at Computational Molecular Biology Symposium

FDA Advisory Committee planned to review Lux Biosciences' NDA for voclosporin

Additional benefits of LAIAs over long-acting human insulin not been proven

AlphaRx continues to develop Indaflex for the Chinese market

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News